TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32897014
Drug: Phenazopyridine 200
Normalized name: phenazopyridine 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenazopyridine 200 mg administered 20 minutes before cystoscopy and then 200 mg every 8 hours (total three doses) with lidocaine gel
Study: 32897014
Drug: Phenazopyridine with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenazopyridine with lidocaine gel
Study: 34127014
Drug: BA (5.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: BA (5.0 g·day‐1 of β‐alanine)
Study: 34127014
Drug: ALK (0.07
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALK (0.07 g·kgFFM‐1·day‐1 of sodium bicarbonate)
Study: 36322882
Drug: Smartphone problem-solving
Normalized name: Solv X
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Smartphone problem-solving therapy and behavioral activation apps
Study: 32440638
Drug: Combination antiretroviral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination antiretroviral therapy (cART)
Study: 33244655
Drug: Conventional fluid
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional fluid treatment
Study: 34583344
Drug: Azithromycin (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin (single oral dose)
Study: 32606341
Drug: Statistical mechanical
Normalized name: PIPERONYL BUTOXIDE TECHNICAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statistical mechanical approach for ensembles of time series designed to preserve statistical properties of empirical time series; specific dosage and duration not available.
Study: 32606341
Drug: Unsupervised, data‐driven
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unsupervised, data‐driven framework for hypothesis testing; specific dosage and duration not available.
Study: 34291443
Drug: Placebo (starch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (starch capsules)
Study: 36709275
Drug: BI 425809
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 425809 10 mg
Study: 36709275
Drug: BI 425809
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 425809 25 mg
Study: 36709275
Drug: BI 425809
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 425809 2 mg
Study: 36709275
Drug: BI 425809
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 425809 5 mg
Study: 35273051
Drug: Mobile Integrated
Normalized name: Chamaemelum nobile extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mobile Integrated Health (MIH) intervention which includes home visits from a community paramedic and telehealth video visits by emergency medicine physicians.
Study: 33463428
Drug: Combined ACL
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined ACL reconstruction and ALL suture tape augmentation (Group 2, n=30)
Study: 32736542
Drug: Wait-list control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wait-list control group (usual care during chemotherapy and aerobic exercise post-chemotherapy)
Study: 34842950
Drug: Docetaxel (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Docetaxel (75 mg/m2/cycle, every 3 weeks, up to 10 cycles)
Study: 34351460
Drug: Mesenchymal stem
Normalized name: Human mesenchymal stem cell
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mesenchymal stem cell therapy (180,000 ± 35,000 cells injected)
Study: 36943254
Drug: Typhoid vaccine
Normalized name: Typhoid vaccine
DrugBank: Typhoid vaccine (DB14022)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Typhoid vaccine
Study: 33544759
Drug: Infant nevirapine
Normalized name: Nevirapine
DrugBank: Nevirapine (DB00238)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Infant nevirapine prophylaxis (no maternal antiretroviral therapy)
Study: 32124574
Drug: Milieu Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milieu Therapy and routine hospital treatment
Study: 32124574
Drug: Routine treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine treatment in the hospital
Study: 35774395
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D supplementation (200,000 IU intramuscular cholecalciferol)
Study: 35774395
Drug: Oral vancomycin
Normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral vancomycin (control)
Study: 35319844
Drug: He's santong
Approvals — FDA: no, EMA: no, PMDA: no
Description: He's santong acupuncture therapy
Study: 33124506
Drug: Intensified Oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensified Oral Hygiene Care (IOHC)
Study: 33124506
Drug: Routine Oral
Normalized name: Peace Out Acne Hero Routine KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine Oral Hygiene Care (Control)
Study: 37948286
Drug: Precision nutrition
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Precision nutrition counseling (six weekly sessions)
Study: 33064852
Drug: Rectal misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rectal misoprostol (preoperative)
Study: 32406112
Drug: linaclotide (290
Approvals — FDA: no, EMA: no, PMDA: no
Description: linaclotide (290 µg)
Study: 33909985
Drug: Usual treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual treatment by an occupational therapist
Study: 34995417
Drug: GSK3640254 tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK3640254 tablet formulation 200 mg
Study: 34995417
Drug: GSK3640254 tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK3640254 tablet formulation 200 mg under high-fat conditions
Study: 33155849
Drug: Diclofenac (any
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac (any formulation)
Study: 34687253
Drug: LL-37 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LL-37 at 0.5 mg/mL
Study: 34687253
Drug: LL-37 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LL-37 at 1.6 mg/mL
Study: 33530828
Drug: Notched peripheral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Notched peripheral intravenous catheter
Study: 34848294
Drug: Pharmacist-facilitated antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacist-facilitated antibiotic timeout
Study: 616118509
Drug: Intravitreal bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravitreal bevacizumab (IVB; 1.5 mg/0.06 cc)
Study: 616118509
Drug: Intravitreal ranibizumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal ranibizumab (IVR; 0.5 mg/0.06 cc)
Study: 33206794
Drug: Green tea
Normalized name: Green Tea
DrugBank: Green tea leaf (DB14307)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Green tea extract (GTE) 150mg, two tablets daily
Study: 33080486
Drug: Single-dose metronidazole
Normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single-dose metronidazole (MTZ)
Study: 33934474
Drug: Gel cream
Normalized name: Versigel Cream for Compounding
DrugBank: Sepia esculenta bone (DB16562)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gel cream containing piroctone olamine, biosaccharide gum-2, stearyl glycyrrhetinate, and zinc l-pyrrolidone carboxylate, applied twice daily for 30 days
Study: 36448321
Drug: Microemulsion gel
Normalized name: cyclosporine microemulsion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Microemulsion gel formula (288 mg α-tocopherol)
Study: 36448321
Drug: Dry solid
Normalized name: Corydalis solida whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dry solid tablet (288 mg α-tocopherol)
Study: 34710946
Drug: Sucrosomial iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sucrosomial iron (60 mg/day for one month)
Study: 34958092
Drug: 3.5 g
Normalized name: Calcium 760 MG/3.5 GM Oral Granule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.5 g of MCH applied as SPLAT MCH (SPLAT3.5)
Study: 34958092
Drug: 3.5 g
Normalized name: Calcium 760 MG/3.5 GM Oral Granule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.5 g of Acer kairomone blend (AKB)
Study: 34958092
Drug: 3.5 g
Normalized name: Calcium 760 MG/3.5 GM Oral Granule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.5 g of acetophenone + green leaf volatiles (PLUS)
Study: 34958092
Drug: 7 g
Normalized name: Vaporizer 1.7 gallon
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7 g of MCH applied as SPLAT MCH (SPLAT7)
Study: 34958092
Drug: 7 g
Normalized name: Vaporizer 1.7 gallon
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7 g of Acer kairomone blend (AKB)
Study: 34958092
Drug: 7 g
Normalized name: Vaporizer 1.7 gallon
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7 g of acetophenone + green leaf volatiles (PLUS)
Study: 36307156
Drug: Recruitment manoeuvres
Normalized name: Humanized Bi-Specific Xmab(R) T Cell Recruiting Antibody Construct Directed Against Cd3 And Cd38
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recruitment manoeuvres (RMs) with sequential high-flow nasal oxygen therapy (HFNO) after extubation
Study: 34708255
Drug: 50 μg
Normalized name: penicillin G 50 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 μg lysergic acid diethylamide (LSD)
Study: 32443412
Drug: Fortified complementary
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fortified complementary food supplements (CFSs)
Study: 34091488
Drug: Oral insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral insulin
Study: 35622456
Drug: E2027 (doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: E2027 (doses ranging from 5 to 1200 mg)
Study: 35622456
Drug: E2027 (doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: E2027 (doses planned for phase 2 study)
Study: 35695863
Drug: Gefitinib treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gefitinib treatment
Study: 36444953
Drug: Oral acetaminophen
Normalized name: acetaminophen Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral acetaminophen before removal of drainage tubes and a second dose at 8 p.m. on the same day.
Study: 36444953
Drug: Routine treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine treatment without acetaminophen (control group).
Study: 35193648
Drug: 6% Hydroxyethyl
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6% Hydroxyethyl starch (HES) 130 solution (Volulyte 6%, Fresenius Kabi, Germany)
Study: 35193648
Drug: Crystalloid solution
Normalized name: Crystal ammonia
DrugBank: Ammonium carbonate (DB15926)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crystalloid solution (Ionolyte, Fresenius Kabi, Germany)
Study: 35979057
Drug: Propofol intravenous
Normalized name: Propofol Intravenous Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol intravenous anesthesia combined with press-needle therapy
Study: 35979057
Drug: Propofol intravenous
Normalized name: Propofol Intravenous Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol intravenous anesthesia
Study: 35762946
Drug: Cognitive behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioural therapy for insomnia (CBTi)
Study: 33152700
Drug: High-dose methotrexate
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose methotrexate (HD‐MTX; 3‐8 g/m2)
Study: 33152700
Drug: HD‐MTX-based therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: HD‐MTX-based therapy
Study: 33152700
Drug: High-dose chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose chemotherapy with autologous stem cell transplantation
Study: 33152700
Drug: Whole-brain radiation
Normalized name: pork brain preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole-brain radiation therapy
Study: 37716952
Drug: atrasentan 1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: atrasentan 1.25 mg/day
Study: 33472677
Drug: Mass drug
Normalized name: Xenon, isotope of mass 129
DrugBank: Xenon Xe-129 (DB17386)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mass drug administration (MDA) for soil-transmitted helminths (STH)
Study: 33724256
Drug: Celecoxib augmentation
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Celecoxib augmentation (n = 18)
Study: 33724256
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual (n = 9)
Study: 33371159
Drug: Shi-style spine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shi-style spine balance manipulation combined with Daoyin therapy
Study: 33834521
Drug: Baricitinib 4-mg
Normalized name: baricitinib 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baricitinib 4-mg plus TCS
Study: 33834521
Drug: Baricitinib 2-mg
Normalized name: baricitinib 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baricitinib 2-mg plus TCS
Study: 33560442
Drug: Standard chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard chemotherapy without rituximab
Study: 35414092
Drug: Internet-based cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-based cognitive behavioral therapy (iCBT) consisting of eight modules focusing on psychoeducation, cognitive restructuring, pacing, and emotion regulation, with weekly written feedback from a trained therapist.
Study: 34488326
Drug: Pethidine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pethidine (100 mg as intravenous infusion)
Study: 32881912
Drug: Sitagliptin (DPP4i)
DrugBank: Sitagliptin (DB01261)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Sitagliptin (DPP4i) at 100mg daily for 28 days
Study: 34812982
Drug: Cytoreductive surgery
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC)
Study: 33145862
Drug: High-dose NSAID
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose NSAID (piroxicam) alone
Study: 33145862
Drug: Paracetamol and
Normalized name: Paracetamol and tramadol only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol and high-dose NSAID combination
Study: 33322280
Drug: Glutamine supplementation
Normalized name: Glutamine
DrugBank: L-Glutamine (DB00130)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glutamine supplementation (20 g/day) and 8% maltodextrin
Study: 34625598
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine (GLAR)
Study: 34857545
Drug: SGLT2 inhibitor
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SGLT2 inhibitor dapagliflozin (5 mg daily)
Study: 33915962
Drug: Reishi Mushroom
Normalized name: REISHI MUSHROOM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reishi Mushroom (lower-dose)
Study: 33915962
Drug: Reishi Mushroom
Normalized name: REISHI MUSHROOM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reishi Mushroom (higher-dose)
Study: 33915962
Drug: Stinging Nettle
Normalized name: Stinging Nettle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stinging Nettle (lower-dose)
Study: 33915962
Drug: Stinging Nettle
Normalized name: Stinging Nettle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stinging Nettle (higher-dose)
Study: 33915962
Drug: Epimedium (lower-dose)
Normalized name: Epimedium grandiflorum top extract
DrugBank: Epimedium grandiflorum top (DB14301)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epimedium (lower-dose)
Study: 33915962
Drug: Epimedium (higher-dose)
Normalized name: Epimedium grandiflorum top extract
DrugBank: Epimedium grandiflorum top (DB14301)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epimedium (higher-dose)
Study: 34644471
Drug: Intranasal oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal oxytocin (48 international units daily)
Study: 39260927
Drug: Evogliptin 10
Normalized name: Evogliptin
DrugBank: Evogliptin (DB12625)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evogliptin 10 mg
Study: 35833454
Drug: Olanzapine (5-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine (5-20 mg/day, titrated every 3-4 days)
Study: 33905493
Drug: 64 mg
Normalized name: sulfur 64 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 64 mg guanabenz
Study: 33905493
Drug: 32 mg
Normalized name: caffeine 32 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 32 mg guanabenz
Study: 33905493
Drug: 16 mg
Normalized name: escin 16 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 16 mg guanabenz
Study: 35488976
Drug: Active control
Normalized name: Accu-Chek Active Control Solution
DrugBank: Pyrithione (DB06815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active control (psychoeducation/supportive therapy)
Study: 32169808
Drug: DCs vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DCs vaccine (group III)
Study: 32169808
Drug: Trans-arterial chemoembolization
Normalized name: Echinacea, aerial parts
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trans-arterial chemoembolization (TACE) and DCs as adjuvant therapy (group I)
Study: 32169808
Drug: Supportive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supportive treatment (group IV)
Study: 33576546
Drug: Episodic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Episodic treatment
Study: 33978070
Drug: Integrated approach
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Integrated approach including balloon uterine stent placement, artificial cycle, intrauterine perfusion of Danshen injection, and oral Chinese medicine
Study: 32084530
Drug: Dexamethasone (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (4 mg or 8 mg)
Study: 32351164
Drug: Ublituximab (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ublituximab (150 mg over 1–4 hours on day 1 and 450–600 mg over 1–3 hours on day 15 and week 24)
Study: 33836810
Drug: Unaccompanied course
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unaccompanied course (no support from psychologist via weekly phone calls)
Study: 33836810
Drug: Accompanied course
Approvals — FDA: no, EMA: no, PMDA: no
Description: Accompanied course (support from a psychologist via weekly phone calls)
Study: 36484872
Drug: Synbiotic capsule
Normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Synbiotic capsule containing 6 × 10^9 CFU Lactobacillus coagulans SC‐208, 6 × 10^9 CFU Lactobacillus indicus HU36 and fructooligosaccharide as a prebiotic, taken twice a day for eight weeks
Study: 36484872
Drug: Placebo, taken
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, taken twice a day for eight weeks
Study: 33771102
Drug: Prenatal exercise
Normalized name: Ardisia crenata root extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prenatal exercise (150 min of moderate‐intensity weekly exercise)
Study: 35235774
Drug: Nicotinamide riboside
Normalized name: Nicotinamide riboside
DrugBank: Nicotinamide riboside (DB14933)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotinamide riboside (NR) 1,000 mg
Study: 35341156
Drug: RG group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: RG group (general treatments combining reduced glutathione)
Study: 35341156
Drug: CHF group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHF group (general treatments combining Chuan Huang Fang)
Study: 35341156
Drug: RG +
Normalized name: DNA, D((2'-O-(2-METHOXYETHYL))M5RC-SP-(2'-O-(2-METHOXYETHYL))RA-(2'-O-(2-METHOXYETHYL))RG-SP-(2'-O-(2-METHOXYETHYL))RG-(2'-O-(2-METHOXYETHYL))RA-SP-T-SP-A-SP-M5C-SP-A-SP-T-SP-T-SP-T-SP-M5C-SP-T-SP-A-SP-(2'-O-(2-METHOXYETHYL))M5RC-(2'-O-(2-METHOXYETHYL))R
Approvals — FDA: no, EMA: no, PMDA: no
Description: RG + CHF group (general treatments combining reduced glutathione and Chuan Huang Fang)
Study: 33136134
Drug: Oral iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral iron supplements plus 200 mg of vitamin C
Study: 33136134
Drug: Oral iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral iron supplements only
Study: 34967656
Drug: Immunosuppressive therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunosuppressive therapy in addition to conventional heart failure therapy
Study: 34967656
Drug: Conventional heart
Normalized name: porcine heart preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional heart failure therapy alone
Study: 32546962
Drug: FDC of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: FDC of fimasartan 120 mg and atorvastatin 40 mg
Study: 32546962
Drug: Separate tablets
Normalized name: Atractylis separate root
DrugBank: Atractylodes lancea root (DB14693)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Separate tablets of fimasartan and atorvastatin
Study: 34180843
Drug: Presentation about
Approvals — FDA: no, EMA: no, PMDA: no
Description: Presentation about the futility of antibiotic treatment of URTIs
Study: 34180843
Drug: Presentation about
Approvals — FDA: no, EMA: no, PMDA: no
Description: Presentation about the adverse effects associated with antibiotics
Study: 32031887
Drug: Early integrated
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early integrated palliative and oncology care (PC), with expected monthly meetings with a PC clinician until death.
Study: 36041655
Drug: Astegolimab 490
Normalized name: Astegolimab
DrugBank: Astegolimab (DB16386)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Astegolimab 490 mg every 4 weeks for 16 weeks
Study: 34477823
Drug: Avoid antiplatelet
Normalized name: simethicone
DrugBank: Simethicone (DB09512)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Avoid antiplatelet therapy (Control)
Study: 34799682
Drug: D-Cycloserine (DCS)
Normalized name: D-Cycloserine
DrugBank: Cycloserine (DB00260)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: D-Cycloserine (DCS) 50 mg
Study: 34799682
Drug: Hydrocortisone (HC)
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Hydrocortisone (HC) 25 mg
Study: 34856181
Drug: Ivermectin (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ivermectin (200 μg/kg) plus Albendazole (400 mg)
Study: 34856181
Drug: Albendazole (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albendazole (400 mg) plus Placebo
Study: 35395204
Drug: gameChange VR
Normalized name: Prostin VR
DrugBank: Alprostadil (DB00770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: gameChange VR therapy plus usual care
Study: 34127100
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy of Transcranial Magnetic Stimulation (rTMS) with Ketamine (CTK)
Study: 34774396
Drug: Extended-release naltrexone
Normalized name: bupropion / naltrexone Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release naltrexone (XR-NTX) continued group